Page 18 - 2019_11 Resto del Mondo-web

Editorials
2124
This will ensure timely treatment with phlebotomies in those patients who otherwise will be classified as ET and who would then carry an increased risk of potentially life-threatening or life-invalidating thrombotic complica- tions. Future studies should also address whether the RBC count in addition to the erythrocyte SR may be sim- ple but highly robust and reproducible indicators of an increased RCM and the hyperviscosity state, respectively, to be used in the diagnosis of PV and when monitoring PV patients for the need for phlebotomy.62
References
1. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
2. Spivak JL, Silver RT. The revised World Health Organization diag- nostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood. 2008;112(2): 231-239.
3. Silver RT, Chow W, Orazi A, Arles SP, Goldsmith SJ. Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. Blood. 2013;122(11):1881-1886.
4. Spivak JL. How I treat polycythemia vera. Blood. 2019;134(4):341- 352.
5. JohanssonPL,Safai-KuttiS,KuttiJ.Anelevatedvenoushaemoglobin concentration cannot be used as a surrogate marker for absolute ery- throcytosis: a study of patients with polycythaemia vera and appar- ent polycythaemia. Br J Haematol. 2005;129(5):701-705.
6. Cassinat B, Laguillier C, Gardin C, et al; PV-Nord Group. Classification of myeloproliferative disorders in the JAK2 era: is there a role for red cell mass? Leukemia. 2008;22(2):452-453.
7. Alvarez-Larran A, Ancochea A, Angona A, et al. Red cell mass meas- urement in patients with clinically suspected diagnosis of poly- cythemia vera or essential thrombocythemia. Haematologica. 2012;97(11):1704-1707.
8. Michiels JJ, Medinger M, Raeve HD, et al. Increased Erythrocyte Count on Top of Bone Marrow Histology but not Serum EPO Level or JAK2 Mutation Load Discriminates between JAK2V617F Mutated Essential Thrombocythemia and Polycythemia Vera. J Hematol Thromb Dis. 2015;3:S1-001.
9. TefferiA,ThieleJ,OraziA,etal.Proposalsandrationaleforrevision of the World Health Organization diagnostic criteria for poly- cythemia vera, essential thrombocythemia, and primary myelofibro- sis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097.
10. Najean Y, Dresch C, Rain J, Chomienne C. Radioisotope investiga- tions for the diagnosis and follow-up of polycythemic patients. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, PA: Saunders; 1995:79- 90.
11. Spivak JL. Polycythemia vera: myths, mechanisms, and manage- ment. Blood. 2002;100(13):4272-4290.
12. Tefferi A. The rise and fall of red cell mass measurement in poly- cythemia vera. Curr Hematol Rep. 2005;4(4):213-217.
13. BarbuiT,ThieleJ,VannucchiAM,TefferiA.Rethinkingthediagnos- tic criteria of polycythemia vera. Leukemia. 2014;28(6):1191-1195.
14. Tefferi A, Barbui T. Polycythemia vera and essential thrombo- cythemia: 2017 update on diagnosis, risk-stratification, and manage- ment. Am J Hematol. 2017;92(1):94-108.
15. Jakovic L, Gotic M, Gisslinger H, et al. The WHO diagnostic criteria for polycythemia vera-role of red cell mass versus hemoglobin/hema- tocrit level and morphology. Ann Hematol. 2018;97(9):1581-1590.
16. Spivak JL. Myeloproliferative Neoplasms. N Engl J Med. 2017;376 (22):2168-2181.
17. Thiele J, Kvasnicka HM. Diagnostic impact of bone marrow histopathology in polycythemia vera (PV). Histol Histopathol. 2005; 20(1):317-328.
18. KvasnickaHM.WHOclassificationofmyeloproliferativeneoplasms (MPN): a critical update. Curr Hematol Malig Rep. 2013;8(4):333- 341.
19. Madelung AB, Bondo H, Stamp I, et al. World Health Organization- defined classification of myeloproliferative neoplasms: morphologi- cal reproducibility and clinical correlations—the Danish experience. Am J Hematol. 2013;88(12):1012-1016.
20.
21.
22. 23. 24.
25.
26.
27.
28.
29. 30. 31.
32.
33. 34.
35. 36.
37.
38.
39.
40.
41. 42.
43. 44.
Gianelli U, Iurlo A, Cattaneo D, Lambertenghi-Deliliers G. Cooperation between pathologists and clinicians allows a better diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms. Expert Rev Hematol. 2014;7(2):255-264. KvasnickaHM,OraziA,ThieleJ,etal.Europeanleukemianetstudy on the reproducibility of bone marrow features in masked poly- cythemia vera and differentiation from essential thrombocythemia. Am J Hematol. 2017;92(10):1062-1067.
Barbui T, Thiele J, Gisslinger H, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014;89(1):52-54.
Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification. Am J Hematol. 2014;89(2):199-202.
Ethier V, Sirhan S, Olney HJ, et al. The 2016 WHO criteria for the diagnosis of polycythemia vera: benefits and potential risks. [e-let- ters]. Blood. 2016. Available at: http://www.bloodjournal.org/con- tent/127/20/2391/tab-e-letters. RumiE,CazzolaM.Diagnosis,riskstratification,andresponseeval- uation in classical myeloproliferative neoplasms. Blood. 2017;129(6):680-692.
Barbui T, Thiele J, Gisslinger H, et al. Diagnostic impact of the revised WHO criteria for polycythemia vera. Am J Hematol. 2017;92(5):417-419.
Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15. Cordua S, Kjaer L, Skov V, et al. Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population. Blood. 2019;134(5):469-479.
Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340(2):115-126. DavìG,PatronoC.Plateletactivationandatherothrombosis.NEngl J Med. 2007;357(24):2482-2494.
Totani L, Evangelista V. Platelet-leukocyte interactions in cardiovas- cular disease and beyond. Arterioscler Thromb Vasc Biol. 2010;30(12):2357-2361.
Hoogeveen RM, Nahrendorf M, Riksen NP, et al. Monocyte and haematopoietic progenitor reprogramming as common mechanism underlying chronic inflammatory and cardiovascular diseases. Eur Heart J. 2018;39(38):3521-3527.
Nahrendorf M. Myeloid cell contributions to cardiovascular health and disease. Nat Med. 2018;24(6):711-720. CollerBS.Leukocytosisandischemicvasculardiseasemorbidityand mortality: is it time to intervene? Arterioscler Thromb Vasc Biol. 2005;25(4):658-670.
Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009;114(4):759-763. Buxhofer-Ausch V, Steurer M, Sormann S, et al. Impact of white blood cells on thrombotic risk in patients with optimized platelet count in essential thrombocythemia. Eur J Haematol. 2018 Mar 30. [Epub ahead of print]
Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019;3(11):1729-1737.
Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544- 1551.
Lussana, F, Carobbio A, Randi ML, et al. A lower intensity of treat- ment may underlie the increased risk of thrombosis in young patients with masked polycythemia vera. Br J Haematol. 2014;2014;167(4):541-546.
Campbell PJ, Scott LM, Buck G, et al. ; United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. Definition of subtypes of essential thrombo- cythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945- 1953. LamyT,DevillersA,BernardM,etal.Inapparentpolycythemiavera: an unrecognized diagnosis. Am J Med. 1997;102(1):14-20.
Thiele J, Kvasnicka HM, Diehl V. Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. Acta Haematol. 2005;113(4):213-219.
Barbui T, Thiele J, Carobbio A, et al. Discriminating between essen- tial thrombocythemia and masked polycythemia vera in JAK2 mutated patients. Am J Hematol. 2014;89(6):588-590.
Barbui T, Thiele J, Kvasnicka HM, et al. Essential thrombocythemia
haematologica | 2019; 104(11)